ADMA Biologics, Inc. (ADMA)

ADMA Biologics, Inc. is trading at $9.48, up 1.45% on the session. The 50 day average sits at $8.74 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 56.4, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $8.28 with resistance near $10.35, so that band frames the current range. Average daily movement is roughly $0.37, or about 3.9% of the share price, which is what any stop placement has to allow for. The overall health score of 71 out of 100 combines a trend score of 75, momentum of 80 and a risk score of 52.

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.